hyb retatrutide effects greatest Weight Loss in TRIUMPH-4 trial, bests Tirzepatide Retatrutide Triple Agonist (GLP-1/GIP/GCG) |

If symptoms persist, dose adjustments or switching to a different medication may be necessary

1 A review article of multiple randomized controlled trials reports an average weight loss of around 16% among users, with some losing as much as 17.4%

In conclusion, GLP-1 receptor agonists did not increase or decrease the risk of thyroid cancer, hyperthyroidism, hypothyroidism, thyroiditis, thyroid mass and goiter

Additionally, the American Society of Anesthesiologists has issued specific guidelines about discontinuing GLP-1 medications before surgery due to delayed gastric emptying concerns, which requires careful planning and medical supervision